Kewaunee Scientific (KEQU) 10-Q 9 Dec 22 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Oct. 31, 2022	Dec. 06, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 31, 2022
Document Transition Report	false
Entity File Number	0-5286
Entity Registrant Name	KEWAUNEE SCIENTIFIC CORP /DE/
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-0715562
Entity Address, Address Line One	2700 West Front Street
Entity Address, City or Town	Statesville,
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28677-2927
City Area Code	704
Local Phone Number	873-7202
Title of 12(b) Security	Common Stock, $2.50 par value
Trading Symbol	KEQU
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,830,200
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000055529
Current Fiscal Year End Date	--04-30

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Income Statement [Abstract]
Net sales	$ 54,564	$ 39,031	$ 104,687	$ 78,524
Cost of products sold	45,863	35,434	89,790	69,253
Gross profit	8,701	3,597	14,897	9,271
Operating expenses	7,946	6,487	14,538	13,252
Operating profit (loss)	755	(2,890)	359	(3,981)
Pension (expense) income	(8)	89	(35)	178
Other income, net	79	46	546	98
Interest expense	(370)	(132)	(754)	(238)
Profit (Loss) before income taxes	456	(2,887)	116	(3,943)
Income tax expense	570	195	949	446
Net loss	(114)	(3,082)	(833)	(4,389)
Less: Net earnings attributable to the non-controlling interest	129	18	157	56
Net loss attributable to Kewaunee Scientific Corporation	$ (243)	$ (3,100)	$ (990)	$ (4,445)
Net loss per share attributable to Kewaunee Scientific Corporation stockholders
Basic (in dollars per share)	$ (0.09)	$ (1.11)	$ (0.35)	$ (1.60)
Diluted (in dollars per share)	$ (0.09)	$ (1.11)	$ (0.35)	$ (1.60)
Weighted average number of common shares outstanding
Basic (in shares)	2,830	2,789	2,819	2,783
Diluted (in shares)	2,830	2,789	2,819	2,783

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (114)	$ (3,082)	$ (833)	$ (4,389)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(237)	(83)	(461)	(159)
Other comprehensive loss	(237)	(83)	(461)	(159)
Comprehensive loss, net of tax	(351)	(3,165)	(1,294)	(4,548)
Less: Comprehensive income attributable to the non-controlling interest	129	18	157	56
Comprehensive loss attributable to Kewaunee Scientific Corporation	$ (480)	$ (3,183)	$ (1,451)	$ (4,604)

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Loss
Beginning balance at Apr. 30, 2021	$ 41,241	$ 6,915	$ 3,807	$ (53)	$ 34,149	$ (3,577)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to Kewaunee Scientific Corporation	(1,345)				(1,345)
Other comprehensive loss	(76)					(76)
Stock-based compensation	238	67	171
Ending balance at Jul. 31, 2021	40,058	6,982	3,978	(53)	32,804	(3,653)
Beginning balance at Apr. 30, 2021	41,241	6,915	3,807	(53)	34,149	(3,577)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to Kewaunee Scientific Corporation	(4,445)
Other comprehensive loss	(159)
Ending balance at Oct. 31, 2021	37,005	6,983	4,107	(53)	29,704	(3,736)
Beginning balance at Jul. 31, 2021	40,058	6,982	3,978	(53)	32,804	(3,653)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to Kewaunee Scientific Corporation	(3,100)				(3,100)
Other comprehensive loss	(83)					(83)
Stock-based compensation	130	1	129
Ending balance at Oct. 31, 2021	37,005	6,983	4,107	(53)	29,704	(3,736)
Beginning balance at Apr. 30, 2022	35,694	6,983	4,483	(53)	28,023	(3,742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to Kewaunee Scientific Corporation	(747)				(747)
Other comprehensive loss	(224)					(224)
Stock-based compensation	(37)	97	(134)
Ending balance at Jul. 31, 2022	34,686	7,080	4,349	(53)	27,276	(3,966)
Beginning balance at Apr. 30, 2022	35,694	6,983	4,483	(53)	28,023	(3,742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to Kewaunee Scientific Corporation	(990)
Other comprehensive loss	(461)
Ending balance at Oct. 31, 2022	34,402	7,084	4,541	(53)	27,033	(4,203)
Beginning balance at Jul. 31, 2022	34,686	7,080	4,349	(53)	27,276	(3,966)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to Kewaunee Scientific Corporation	(243)				(243)
Other comprehensive loss	(237)					(237)
Stock-based compensation	196	4	192
Ending balance at Oct. 31, 2022	$ 34,402	$ 7,084	$ 4,541	$ (53)	$ 27,033	$ (4,203)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Oct. 31, 2022	Apr. 30, 2022
Current Assets:
Cash and cash equivalents	$ 9,419	$ 4,433
Restricted cash	6,898	2,461
Receivables, less allowance; $379; $357, on each respective date	41,472	41,254
Inventories	24,502	23,796
Note Receivable	0	13,457
Prepaid expenses and other current assets	8,323	6,164
Total Current Assets	90,614	91,565
Property, plant and equipment, at cost	61,246	60,326
Accumulated depreciation	(46,639)	(45,205)
Net Property, Plant and Equipment	14,607	15,121
Right of use assets	9,908	7,573
Other assets	3,989	4,514
Total Assets	119,118	118,773
Current Liabilities:
Short-term borrowings	0	1,588
Current portion of financing liability	608	575
Current portion of financing lease liability	74	126
Current portion of operating lease liabilities	1,999	1,319
Accounts payable	23,050	27,316
Employee compensation and amounts withheld	4,309	4,504
Deferred revenue	11,398	3,529
Other accrued expenses	1,420	3,336
Total Current Liabilities	42,858	42,293
Long-term portion of financing liability	28,459	28,775
Long-term portion of financing lease liability	219	228
Long-term portion of operating lease liabilities	7,746	6,179
Accrued pension and deferred compensation costs	3,924	4,159
Deferred income taxes	406	428
Other non-current liabilities	497	531
Total Liabilities	84,109	82,593
Commitments and Contingencies
Stockholders' Equity:
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,833 shares; 2,793 shares; – Outstanding – 2,830 shares; 2,790 shares, on each respective date	7,084	6,983
Additional paid-in-capital	4,541	4,483
Retained earnings	27,033	28,023
Accumulated other comprehensive loss	(4,203)	(3,742)
Common stock in treasury, at cost, 3 shares, on each respective date	(53)	(53)
Total Kewaunee Scientific Corporation Stockholders' Equity	34,402	35,694
Non-controlling interest	607	486
Total Stockholders' Equity	35,009	36,180
Total Liabilities and Stockholders' Equity	$ 119,118	$ 118,773

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Oct. 31, 2022	Apr. 30, 2022
Current Assets:
Allowance for receivables	$ 379	$ 357
Stockholders' Equity:
Common stock, par value (in dollars per share)	$ 2.50	$ 2.50
Common stock, shares authorized (in shares)	5,000	5,000
Common stock, shares issued (in shares)	2,833	2,793
Common stock, shares outstanding (in shares)	2,830	2,790
Treasury stock, shares (in shares)	3	3

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Cash flows from operating activities:
Net loss	$ (833)	$ (4,389)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,433	1,396
Bad debt provision	(8)	(2)
Stock-based compensation expense	368	366
Deferred income taxes	(22)	72
Change in assets and liabilities:
Receivables	(209)	(2,971)
Inventories	(706)	(1,603)
Income tax receivable	0	180
Accounts payable and other accrued expenses	(6,412)	3,145
Deferred revenue	7,869	(72)
Other, net	(2,066)	(2,193)
Net cash used in operating activities	(586)	(6,071)
Cash flows from investing activities:
Capital expenditures	(919)	(930)
Net cash used in investing activities	(919)	(930)
Cash flows from financing activities:
Proceeds from short-term borrowings	4,431	28,641
Repayments on short-term borrowings	(6,019)	(21,774)
Proceeds from sale-leaseback financing transaction	13,456	0
Payments on sale-leaseback financing transaction	(282)	0
Payments on long-term lease obligations	(61)	(10)
Net cash provided by financing activities	11,525	6,857
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(597)	(55)
Increase (decrease) in cash, cash equivalents and restricted cash	9,423	(199)
Cash, cash equivalents and restricted cash, beginning of period	6,894	5,731
Cash, cash equivalents and restricted cash, end of period	$ 16,317	$ 5,532

Financial Information

Financial Information	6 Months Ended
	Oct. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Information	Financial Information The unaudited interim Condensed Consolidated Financial Statements of Kewaunee Scientific Corporation (the "Company") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading. These interim Condensed Consolidated Financial Statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's 2022 Annual Report on Form 10-K . The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The Condensed Consolidated Balance Sheet as of April 30, 2022 included in this interim period filing has been derived from the audited consolidated financial statements at that date, but does not include all of the information and related notes required by GAAP for complete financial statements. The preparation of the interim Condensed Consolidated Financial Statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	6 Months Ended
	Oct. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less. During the periods ended October 31, 2022 and April 30, 2022, the Company had cash deposits in excess of FDIC insured limits. The Company has not experienced any losses from such deposits. Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders. The Company includes restricted cash along with the cash balance for presentation in the Condensed Consolidated Statements of Cash Flows. The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows: October 31, 2022 April 30, 2022 Cash and cash equivalents $ 9,419 $ 4,433 Restricted cash 6,898 2,461 Total cash, cash equivalents and restricted cash $ 16,317 $ 6,894

Revenue Recognition

Revenue Recognition	6 Months Ended
	Oct. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue RecognitionThe Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company's revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company's revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract. Disaggregated Revenue A summary of net sales transferred to customers over time and at a point in time for the periods ended October 31, 2022 and October 31, 2021 is as follows (in thousands): Three Months Ended October 31, 2022 October 31, 2021 Domestic International Total Domestic International Total Over Time $ 36,374 $ 16,573 $ 52,947 $ 28,450 $ 9,097 $ 37,547 Point in Time 1,617 — 1,617 1,484 — 1,484 Total $ 37,991 $ 16,573 $ 54,564 $ 29,934 $ 9,097 $ 39,031 Six Months Ended October 31, 2022 October 31, 2021 Domestic International Total Domestic International Total Over Time $ 71,727 $ 29,228 $ 100,955 $ 57,102 $ 18,927 $ 76,029 Point in Time 3,732 — 3,732 2,495 — 2,495 Total $ 75,459 $ 29,228 $ 104,687 $ 59,597 $ 18,927 $ 78,524 Contract Balances The closing balances of contract assets included $12,742,000 in accounts receivable and $1,629,000 in other assets at October 31, 2022. The opening balance of contract assets arising from contracts with customers included $9,287,000 in accounts receivable and $1,293,000 in other assets at April 30, 2022. The closing and opening balances of contract liabilities included in deferred revenue arising from contracts with customers were $11,398,000 at October 31, 2022 and $3,529,000 at April 30, 2022. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue which are disclosed in the Condensed Consolidated Balance Sheets and in the Notes to the Condensed Consolidated Financial Statements. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms and are included in receivables on the Condensed Consolidated Balance Sheets. Receivables are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. Approximately 100% of the contract liability balances at April 30, 2022 and October 31, 2022 are expected to be recognized as revenue during the respective succeeding 12 months.

Inventories

Inventories	6 Months Ended
	Oct. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories The Company measures inventory using the first-in, first-out ("FIFO") method at the lower of cost or net realizable value. Inventories consisted of the following (in thousands): October 31, 2022 April 30, 2022 Finished products $ 4,250 $ 4,555 Work in process 3,266 2,893 Raw materials 16,986 16,348 Total $ 24,502 $ 23,796 The Company's International subsidiaries' inventories were $3,224,000 at October 31, 2022 and $2,811,000 at April 30, 2022 and are included in the above tables.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Oct. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company's financial instruments consist primarily of cash and equivalents, mutual funds, and the cash surrender value of life insurance policies. The carrying value of these assets and liabilities approximates their fair value. The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 and April 30, 2022 (in thousands): October 31, 2022 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 979 $ — $ 979 Cash surrender value of life insurance policies (1) — 1,317 1,317 Total $ 979 $ 1,317 $ 2,296 Financial Liabilities Non-qualified compensation plans (2) $ — $ 2,733 $ 2,733 Total $ — $ 2,733 $ 2,733 April 30, 2022 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,219 $ — $ 1,219 Cash surrender value of life insurance policies (1) — 1,371 1,371 Total $ 1,219 $ 1,371 $ 2,590 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,003 $ 3,003 Total $ — $ 3,003 $ 3,003 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits.

Long-term Debt and Other Credit

Long-term Debt and Other Credit Arrangements	6 Months Ended
	Oct. 31, 2022
Debt Disclosure [Abstract]
Long-term Debt and Other Credit Arrangements	Long-term Debt and Other Credit Arrangements At April 30, 2022, advances of $1.6 million were outstanding under the Company's revolving credit facility. The Company had standby letters of credit outstanding of $716,000 at April 30, 2022. Amounts available under the revolving credit facility were $2.4 million at April 30, 2022. At April 30, 2022, the Company was in compliance with all the financial covenants under its revolving credit facility. On June 27, 2022, the Company terminated the Credit Agreement with Wells Fargo, National Bank. At the time of termination, there were no borrowings under the Credit Agreement, and the Company did not incur any material termination penalties as a result of the termination.

Sale-Leaseback Financing Transa

Sale-Leaseback Financing Transaction	6 Months Ended
	Oct. 31, 2022
Financing Liability [Abstract]
Sale-Leaseback Financing Transaction	Sale-Leaseback Financing Transaction On December 22, 2021, the Company entered into an Agreement for Purchase and Sale of Real Property with CAI Investments Sub-Series 100 LLC, a Nevada limited liability company (the "Buyer"), for the Company’s headquarters and manufacturing facilities (the "Property") located at 2700 West Front Street in Statesville, North Carolina (the "Sale Agreement"). The Sale Agreement was finalized on March 24, 2022 and coincided with the Company and the Buyer entering into a 20-year lease, effective on such date, between the Company and CAI Investments Medical Products I Master Lessee LLC ("Lessor"), an affiliate of Buyer (the "Lease Agreement"). At the same time, the Buyer and its affiliates formed a new, debt-financed affiliate, CAI Investments Medical Products I, DST ("Trust"), and contributed the Property to the Trust. According to the terms of the contemporaneous lease, the Trust leased the Property to its affiliated Lessor, which in turn sub-leased the Property to the Company (together with the Sale Agreement, the "Sale-Leaseback Arrangement"). The Sale-Leaseback Arrangement is repayable over a 20-year term, with four renewal options of five years each. Under the terms of the Lease Agreement, the Company’s initial basic rent is approximately $158,000 per month, with annual increases of approximately 2% each year of the initial term. The Company accounted for the Sale-Leaseback Arrangement as a financing transaction with the Buyer in accordance with ASC 842, "Leases," as the Lease Agreement was determined to be a finance lease. The Company concluded the Lease Agreement met the qualifications to be classified as a finance lease due to the significance of the present value of the lease payments, using a discount rate of 4.75% to reflect the Company’s incremental borrowing rate, compared to the fair value of the leased property as of the lease commencement date. In measuring the lease payments for the present value analysis, the Company elected the practical expedient to combine the lease component (the leased facilities) with the non-lease component (property management provided by the Buyer/Lessor) into a single lease component. The presence of a finance lease indicates that control of the Property has not transferred to the Buyer/Lessor and, as such, the transaction was deemed a failed sale-leaseback and must be accounted for as a financing arrangement. As a result of this determination, the Company is viewed as having received the sale proceeds from the Buyer/Lessor in the form of a hypothetical loan collateralized by its leased facilities. The hypothetical loan is payable as principal and interest in the form of “lease payments” to the Buyer/Lessor. As such, the Company will not derecognize the Property from its books for accounting purposes until the lease ends. No gain or loss was recognized under GAAP related to the Sale-Leaseback Arrangement. As of October 31, 2022, the carrying value of the financing liability was $29,067,000, net of $738,000 in debt issuance costs, of which $608,000 was classified as current on the Consolidated Balance Sheet with $28,459,000 classified as long-term. As of April 30, 2022, the carrying value of the financing liability was $29,350,000, net of $768,000 in debt issuance costs, of which $575,000 was classified as current on the Consolidated Balance Sheet with $28,775,000 classified as long-term. The monthly lease payments are split between a reduction of principal and interest expense using the effective interest rate method. Interest expense associated with the financing arrangement was $330,000 and $662,000 for the three and six months ended October 31, 2022, respectively. The Company will depreciate the building down to zero over the 20-year assumed economic life of the Property so that at the end of the lease term, the remaining carrying amount of the financing liability will equal the carrying amount of the land of $41,000. Remaining future cash payments related to the financing liability as of October 31, 2022 are as follows: ($ in thousands) Remainder of 2023 $ 948 2024 1,931 2025 1,970 2026 2,009 2027 2,050 Thereafter 35,958 Total Minimum Liability Payments 44,866 Imputed Interest (15,799) Total $ 29,067

Leases

Leases	6 Months Ended
	Oct. 31, 2022
Leases [Abstract]
Leases	Leases The Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At October 31, 2022 and April 30, 2022, right-of-use assets totaled $9,908,000 and $7,573,000, respectively. Operating cash paid to settle lease liabilities was $1,026,000 and $1,006,000 for the six months ended October 31, 2022 and October 31, 2021, respectively. The Company's leases have remaining lease terms of up to 9 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $900,000 and $1,734,000 for the three and six months ended October 31, 2022, inclusive of period cost for short-term leases, not included in lease liabilities, of $398,000 and $708,000. Operating lease expenses were $707,000 and $1,555,000 for the three and six months ended October 31, 2021, inclusive of period cost for short-term leases, not included in lease liabilities, of $201,000 and $549,000. At October 31, 2022, the weighted average remaining lease term for the capitalized operating leases was 5.5 years and the weighted average discount rate was 4.9%. For the financing leases, the weighted average remaining lease term was 3.6 years and the weighted average discount rate was 7.0%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable. Future minimum lease payments under non-cancelable leases as of October 31, 2022 were as follows: Operating Financing Remainder of fiscal 2023 $ 1,213 $ 16 2024 2,254 90 2025 2,100 90 2026 1,915 71 2027 1,652 — Thereafter 2,500 — Total Minimum Lease Payments 11,634 267 Imputed Interest (1,889) (32) Total $ 9,745 $ 235
Leases	Leases The Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At October 31, 2022 and April 30, 2022, right-of-use assets totaled $9,908,000 and $7,573,000, respectively. Operating cash paid to settle lease liabilities was $1,026,000 and $1,006,000 for the six months ended October 31, 2022 and October 31, 2021, respectively. The Company's leases have remaining lease terms of up to 9 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $900,000 and $1,734,000 for the three and six months ended October 31, 2022, inclusive of period cost for short-term leases, not included in lease liabilities, of $398,000 and $708,000. Operating lease expenses were $707,000 and $1,555,000 for the three and six months ended October 31, 2021, inclusive of period cost for short-term leases, not included in lease liabilities, of $201,000 and $549,000. At October 31, 2022, the weighted average remaining lease term for the capitalized operating leases was 5.5 years and the weighted average discount rate was 4.9%. For the financing leases, the weighted average remaining lease term was 3.6 years and the weighted average discount rate was 7.0%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable. Future minimum lease payments under non-cancelable leases as of October 31, 2022 were as follows: Operating Financing Remainder of fiscal 2023 $ 1,213 $ 16 2024 2,254 90 2025 2,100 90 2026 1,915 71 2027 1,652 — Thereafter 2,500 — Total Minimum Lease Payments 11,634 267 Imputed Interest (1,889) (32) Total $ 9,745 $ 235

Earnings Per Share

Earnings Per Share	6 Months Ended
	Oct. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is based on the weighted average number of common shares outstanding during the year. Diluted earnings per share reflects the assumed exercise of outstanding options and the conversion of restricted stock units ("RSUs") under the Company's various stock compensation plans, except when RSUs and options have an antidilutive effect. There were 94,930 and 128,704 antidilutive RSUs and options outstanding at October 31, 2022 and October 31, 2021, respectively. The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands): Three Months Ended Six Months Ended October 31, 2022 October 31, 2021 October 31, 2022 October 31, 2021 Basic 2,830 2,789 2,819 2,783 Dilutive effect of stock options and RSUs — — — — Weighted average common shares outstanding - diluted 2,830 2,789 2,819 2,783

Stock Options and Stock-based C

Stock Options and Stock-based Compensation	6 Months Ended
	Oct. 31, 2022
Equity [Abstract]
Stock Options and Stock-based Compensation	Stock Options and Stock-based Compensation The Company recognizes compensation costs related to stock options and other stock awards granted by the Company as operating expenses over their vesting period. In June 2022, the Company granted 54,279 RSUs under the 2017 Omnibus Incentive Plan ("2017 Plan"). These RSUs include a service component that vests over a three-year period. The recognized expense is based upon the vesting period for service criteria. The Company recorded stock-based compensation expense during the three and six months ended October 31, 2022 of $196,000 and $327,000, respectively, with the remaining estimated stock-based compensation expense of $1,173,000 to be recorded over the remaining vesting periods. The Company recorded stock-based compensation expense during the three and six months ended October 31, 2021 of $131,000 and $325,000, respectively. Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines were $41,000 for each of the six month periods ended October 31, 2022 and October 31, 2021 and were also included in the stock-based compensation on the Condensed Consolidated Statements of Cash Flows.

Income Taxes

Income Taxes	6 Months Ended
	Oct. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	. Income Taxes Income tax expense of $570,000 and $949,000 was recorded for the three and six months ended October 31, 2022, respectively. Income tax expense of $195,000 and $446,000 was recorded for the three and six months ended October 31, 2021, respectively. The effective tax rate was 125.0% and 818.1% for the three and six months ended October 31, 2022, respectively. The effective tax rate was (6.8)% and (11.3)% for the three and six months ended October 31, 2021, respectively. The change in the effective tax rate for the period is primarily due to the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21% and the recording of a valuation allowance against the deferred tax asset which resulted in the elimination of any U.S. income tax benefit. In August 2019, the Company revoked its indefinite reinvestment of foreign unremitted earnings position in compliance with ASC 740 "Income Taxes" and terminated its indefinite reinvestment of unremitted earnings assertion for the Singapore, China, and Kewaunee Labway India Pvt. Ltd. international subsidiaries. The Company has a deferred tax liability of $1,117,000 and $976,000 for the withholding tax related to Kewaunee Labway India Pvt. Ltd. as of October 31, 2022 and April 30, 2022,

Defined Benefit Pension Plans

Defined Benefit Pension Plans	6 Months Ended
	Oct. 31, 2022
Retirement Benefits [Abstract]
Defined Benefit Pension Plans	Defined Benefit Pension Plans The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. There were no Company contributions paid to the plans for the three and six months ended October 31, 2022 and October 31, 2021. The Company assumed an expected long-term rate of return of 7.75% for the periods ended October 31, 2022 and October 31, 2021. Pension expense / (income) consisted of the following (in thousands): Three Months Ended October 31, 2022 October 31, 2021 Service cost $ — $ — Interest cost 100 177 Expected return on plan assets (166) (401) Recognition of net loss 74 135 Net periodic pension expense (income) $ 8 $ (89) Six Months Ended October 31, 2022 October 31, 2021 Service cost $ — $ — Interest cost 422 354 Expected return on plan assets (701) (802) Recognition of net loss 314 270 Net periodic pension expense (income) $ 35 $ (178)

Segment Information

Segment Information	6 Months Ended
	Oct. 31, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information The Company's operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company's foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments. The following tables provide financial information by business segments for the periods ended October 31, 2022 and 2021 (in thousands): Domestic International Corporate / Total Three months ended October 31, 2022 Revenues from external customers $ 37,991 $ 16,573 $ — $ 54,564 Intersegment revenues 650 3,335 (3,985) — Earnings (loss) before income taxes 491 1,856 (1,891) 456 Three months ended October 31, 2021 Revenues from external customers $ 29,934 $ 9,097 $ — $ 39,031 Intersegment revenues 170 571 (741) — Earnings (loss) before income taxes (2,095) 578 (1,370) (2,887) Domestic International Corporate / Total Six months ended October 31, 2022 Revenues from external customers $ 75,459 $ 29,228 $ — $ 104,687 Intersegment revenues 1,446 4,956 (6,402) — Earnings (loss) before income taxes 589 2,950 (3,423) 116 Six months ended October 31, 2021 Revenues from external customers $ 59,597 $ 18,927 $ — $ 78,524 Intersegment revenues 345 1,136 (1,481) — Earnings (loss) before income taxes (2,304) 1,242 (2,881) (3,943)

New Accounting Standards

New Accounting Standards	6 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
New Accounting Standards	New Accounting StandardsIn June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company will adopt this standard in fiscal year 2024. The Company does not expect the adoption of this standard to have a significant impact on the Company's consolidated financial position or results of operations.

New Accounting Standards Signif

New Accounting Standards Significant Accounting Policies (Policies)	6 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
New Accounting Standards	In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company will adopt this standard in fiscal year 2024. The Company does not expect the adoption of this standard to have a significant impact on the Company's consolidated financial position or results of operations.

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	6 Months Ended
	Oct. 31, 2022
Cash and Cash Equivalents [Abstract]
Schedule of Cash, Cash Equivalents, and Restricted Cash	The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows: October 31, 2022 April 30, 2022 Cash and cash equivalents $ 9,419 $ 4,433 Restricted cash 6,898 2,461 Total cash, cash equivalents and restricted cash $ 16,317 $ 6,894

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Oct. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	A summary of net sales transferred to customers over time and at a point in time for the periods ended October 31, 2022 and October 31, 2021 is as follows (in thousands): Three Months Ended October 31, 2022 October 31, 2021 Domestic International Total Domestic International Total Over Time $ 36,374 $ 16,573 $ 52,947 $ 28,450 $ 9,097 $ 37,547 Point in Time 1,617 — 1,617 1,484 — 1,484 Total $ 37,991 $ 16,573 $ 54,564 $ 29,934 $ 9,097 $ 39,031 Six Months Ended October 31, 2022 October 31, 2021 Domestic International Total Domestic International Total Over Time $ 71,727 $ 29,228 $ 100,955 $ 57,102 $ 18,927 $ 76,029 Point in Time 3,732 — 3,732 2,495 — 2,495 Total $ 75,459 $ 29,228 $ 104,687 $ 59,597 $ 18,927 $ 78,524

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Oct. 31, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consisted of the following (in thousands): October 31, 2022 April 30, 2022 Finished products $ 4,250 $ 4,555 Work in process 3,266 2,893 Raw materials 16,986 16,348 Total $ 24,502 $ 23,796

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Oct. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis	The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 and April 30, 2022 (in thousands): October 31, 2022 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 979 $ — $ 979 Cash surrender value of life insurance policies (1) — 1,317 1,317 Total $ 979 $ 1,317 $ 2,296 Financial Liabilities Non-qualified compensation plans (2) $ — $ 2,733 $ 2,733 Total $ — $ 2,733 $ 2,733 April 30, 2022 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,219 $ — $ 1,219 Cash surrender value of life insurance policies (1) — 1,371 1,371 Total $ 1,219 $ 1,371 $ 2,590 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,003 $ 3,003 Total $ — $ 3,003 $ 3,003 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits.

Sale-Leaseback Financing Tran_2

Sale-Leaseback Financing Transaction (Tables)	6 Months Ended
	Oct. 31, 2022
Financing Liability [Abstract]
Schedule of Remaining Future Cash Payments for Financing Liability	Remaining future cash payments related to the financing liability as of October 31, 2022 are as follows: ($ in thousands) Remainder of 2023 $ 948 2024 1,931 2025 1,970 2026 2,009 2027 2,050 Thereafter 35,958 Total Minimum Liability Payments 44,866 Imputed Interest (15,799) Total $ 29,067

Leases (Tables)

Leases (Tables)	6 Months Ended
	Oct. 31, 2022
Leases [Abstract]
Schedule of Operating Lease Maturity	Future minimum lease payments under non-cancelable leases as of October 31, 2022 were as follows: Operating Financing Remainder of fiscal 2023 $ 1,213 $ 16 2024 2,254 90 2025 2,100 90 2026 1,915 71 2027 1,652 — Thereafter 2,500 — Total Minimum Lease Payments 11,634 267 Imputed Interest (1,889) (32) Total $ 9,745 $ 235
Schedule of Finance Lease Maturity	Future minimum lease payments under non-cancelable leases as of October 31, 2022 were as follows: Operating Financing Remainder of fiscal 2023 $ 1,213 $ 16 2024 2,254 90 2025 2,100 90 2026 1,915 71 2027 1,652 — Thereafter 2,500 — Total Minimum Lease Payments 11,634 267 Imputed Interest (1,889) (32) Total $ 9,745 $ 235

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Oct. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands): Three Months Ended Six Months Ended October 31, 2022 October 31, 2021 October 31, 2022 October 31, 2021 Basic 2,830 2,789 2,819 2,783 Dilutive effect of stock options and RSUs — — — — Weighted average common shares outstanding - diluted 2,830 2,789 2,819 2,783

Defined Benefit Pension Plans (

Defined Benefit Pension Plans (Tables)	6 Months Ended
	Oct. 31, 2022
Retirement Benefits [Abstract]
Pension Expenses	Pension expense / (income) consisted of the following (in thousands): Three Months Ended October 31, 2022 October 31, 2021 Service cost $ — $ — Interest cost 100 177 Expected return on plan assets (166) (401) Recognition of net loss 74 135 Net periodic pension expense (income) $ 8 $ (89) Six Months Ended October 31, 2022 October 31, 2021 Service cost $ — $ — Interest cost 422 354 Expected return on plan assets (701) (802) Recognition of net loss 314 270 Net periodic pension expense (income) $ 35 $ (178)

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Oct. 31, 2022
Segment Reporting [Abstract]
Segment Information	The following tables provide financial information by business segments for the periods ended October 31, 2022 and 2021 (in thousands): Domestic International Corporate / Total Three months ended October 31, 2022 Revenues from external customers $ 37,991 $ 16,573 $ — $ 54,564 Intersegment revenues 650 3,335 (3,985) — Earnings (loss) before income taxes 491 1,856 (1,891) 456 Three months ended October 31, 2021 Revenues from external customers $ 29,934 $ 9,097 $ — $ 39,031 Intersegment revenues 170 571 (741) — Earnings (loss) before income taxes (2,095) 578 (1,370) (2,887) Domestic International Corporate / Total Six months ended October 31, 2022 Revenues from external customers $ 75,459 $ 29,228 $ — $ 104,687 Intersegment revenues 1,446 4,956 (6,402) — Earnings (loss) before income taxes 589 2,950 (3,423) 116 Six months ended October 31, 2021 Revenues from external customers $ 59,597 $ 18,927 $ — $ 78,524 Intersegment revenues 345 1,136 (1,481) — Earnings (loss) before income taxes (2,304) 1,242 (2,881) (3,943)

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Oct. 31, 2022	Apr. 30, 2022	Oct. 31, 2021	Apr. 30, 2021
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 9,419	$ 4,433
Restricted cash	6,898	2,461
Total cash, cash equivalents and restricted cash	$ 16,317	$ 6,894	$ 5,532	$ 5,731

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Sales Transferred to Customers at a Point in Time and Over Time (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	$ 54,564	$ 39,031	$ 104,687	$ 78,524
Over Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	52,947	37,547	100,955	76,029
Point in Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	1,617	1,484	3,732	2,495
Domestic
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	37,991	29,934	75,459	59,597
Domestic | Over Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	36,374	28,450	71,727	57,102
Domestic | Point in Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	1,617	1,484	3,732	2,495
International
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	16,573	9,097	29,228	18,927
International | Over Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	16,573	9,097	29,228	18,927
International | Point in Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	$ 0	$ 0	$ 0	$ 0

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Oct. 31, 2022	Apr. 30, 2022
Disaggregation of Revenue [Line Items]
Contract liabilities	$ 11,398	$ 3,529
Contract liability recognized as revenue percentage	100%	100%
Accounts receivable
Disaggregation of Revenue [Line Items]
Contract assets	$ 12,742	$ 9,287
Other assets
Disaggregation of Revenue [Line Items]
Contract assets	$ 1,629	$ 1,293

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Apr. 30, 2022
Inventory Disclosure [Abstract]
Finished products	$ 4,250	$ 4,555
Work in process	3,266	2,893
Raw materials	16,986	16,348
Total	$ 24,502	$ 23,796

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Apr. 30, 2022
Inventory [Line Items]
Inventories	$ 24,502	$ 23,796
International Subsidiaries
Inventory [Line Items]
Inventories	$ 3,224	$ 2,811

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis (Detail) $ in Thousands	Oct. 31, 2022 USD ($) CompensationPlan	Apr. 30, 2022 USD ($) CompensationPlan
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	$ 2,296	$ 2,590
Financial Liabilities	$ 2,733	$ 3,003
Number of non-qualified compensation plans maintained | CompensationPlan	2	2
Non-qualified compensation plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities	$ 2,733	$ 3,003
Trading securities held in non-qualified compensation plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	979	1,219
Cash surrender value of life insurance policies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	1,317	1,371
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	979	1,219
Financial Liabilities	0	0
Level 1 | Non-qualified compensation plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities	0	0
Level 1 | Trading securities held in non-qualified compensation plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	979	1,219
Level 1 | Cash surrender value of life insurance policies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	0	0
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	1,317	1,371
Financial Liabilities	2,733	3,003
Level 2 | Non-qualified compensation plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities	2,733	3,003
Level 2 | Trading securities held in non-qualified compensation plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	0	0
Level 2 | Cash surrender value of life insurance policies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	$ 1,317	$ 1,371

Long-term Debt and Other Cred_2

Long-term Debt and Other Credit Arrangements (Details) - USD ($) $ in Thousands	Jun. 27, 2022	Apr. 30, 2022
Debt Instrument [Line Items]
Remaining borrowing capacity		$ 2,400
Long-term debt	$ 0
Advance Amount One
Debt Instrument [Line Items]
Outstanding advances under the long-term debt		1,600
Advance Amount Two
Debt Instrument [Line Items]
Outstanding advances under the long-term debt		$ 716

Sale-Leaseback Financing Tran_3

Sale-Leaseback Financing Transaction - Narrative (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Oct. 31, 2022 USD ($)	Oct. 31, 2022 USD ($) renewalOption	Apr. 30, 2022 USD ($)
Financing Liability [Abstract]
Term of agreement	20 years	20 years
Number of renewal options | renewalOption		4
Renewal term	5 years	5 years
Initial basic monthly rent		$ 158
Annual rental increase, as a percent		2%
Discount rate	4.75%	4.75%
Gain (loss) on sale leaseback agreement		$ 0
Financing liability	$ 29,067	29,067	$ 29,350
Debt issuance costs on financing liability	738	738	768
Current portion of financing liability	608	608	575
Long-term portion of financing liability	28,459	28,459	28,775
Interest expense on financing liability	330	662
Financing Liability [Line Items]
Property, plant and equipment, at cost	61,246	$ 61,246	$ 60,326
Building
Financing Liability [Line Items]
Useful Life (in years)		20 years
Land
Financing Liability [Line Items]
Property, plant and equipment, at cost	$ 41	$ 41

Sale-Leaseback Financing Tran_4

Sale-Leaseback Financing Transaction - Remaining Future Cash Payments (Details) - USD ($) $ in Thousands	Oct. 31, 2022	Apr. 30, 2022
Financing Liability [Abstract]
Remainder of 2023	$ 948
2024	1,931
2025	1,970
2026	2,009
2027	2,050
Thereafter	35,958
Total Minimum Liability Payments	44,866
Imputed Interest	(15,799)
Total	$ 29,067	$ 29,350

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021	Apr. 30, 2022
Leases [Abstract]
Right of use assets	$ 9,908		$ 9,908		$ 7,573
Operating cash paid to settle lease liabilities			$ 1,026	$ 1,006
Remaining lease term (in years)			9 years
Option to extend, term (in years)			5 years
Option to terminate, term (in years)			1 year
Operating lease, expense	900	$ 707	$ 1,734	1,555
Operating lease, short term, expense	$ 398	$ 201	$ 708	$ 549
Weighted average remaining lease term, operating lease (in years)	5 years 6 months		5 years 6 months
Weighted average discount rate, operating lease	4.90%		4.90%
Weighted average remaining lease term, finance lease (in years)	3 years 7 months 6 days		3 years 7 months 6 days
Weighted average discount rate, finance lease	7%		7%

Leases - Schedule of Operating

Leases - Schedule of Operating and Finance Lease Maturity (Details) $ in Thousands	Oct. 31, 2022 USD ($)
Operating
Remainder of fiscal 2023	$ 1,213
2024	2,254
2025	2,100
2026	1,915
2027	1,652
Thereafter	2,500
Total Minimum Lease Payments	11,634
Imputed Interest	(1,889)
Total	9,745
Financing
Remainder of fiscal 2023	16
2024	90
2025	90
2026	71
2027	0
Thereafter	0
Total Minimum Lease Payments	267
Imputed Interest	(32)
Total	$ 235

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Earnings Per Share [Abstract]
Anti-dilutive options exclude from computation of earning per share (in shares)	94,930	128,704

Earnings Per Share Schedule of

Earnings Per Share Schedule of Earnings Per Common Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Weighted average number of common shares outstanding
Basic (in shares)	2,830	2,789	2,819	2,783
Dilutive effect of stock options and RSUs (in shares)	0	0	0	0
Weighted average common shares outstanding - diluted (in shares)	2,830	2,789	2,819	2,783

Stock Options and Stock-Based_2

Stock Options and Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines				$ 41	$ 41
2017 Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 196	$ 131	327	$ 325
Remaining estimated compensation expense		$ 1,173		$ 1,173
2017 Plan | Restricted Stock Units (RSUs) | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in shares)	54,279
Vesting period (in years)	3 years

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021	Apr. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 570	$ 195	$ 949	$ 446
Effective income tax rate	125%	(6.80%)	818.10%	(11.30%)
Deferred tax liability, global tax exposure for unremitted earnings of international subsidiaries	$ 1,117		$ 1,117		$ 976

Defined Benefit Pension Plans -

Defined Benefit Pension Plans - Additional Information (Detail) - USD ($)	6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Retirement Benefits [Abstract]
Employer contributions	$ 0	$ 0
Assumed as expected long-term rate of return (as a percent)	7.75%	7.75%

Defined Benefit Pension Plans_2

Defined Benefit Pension Plans - Pension Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Retirement Benefits [Abstract]
Service cost	$ 0	$ 0	$ 0	$ 0
Interest cost	100	177	422	354
Expected return on plan assets	(166)	(401)	(701)	(802)
Recognition of net loss	74	135	314	270
Net periodic pension expense (income)	$ 8	$ (89)	$ 35	$ (178)

Segment Information - Additiona

Segment Information - Additional Information (Detail)	6 Months Ended
	Oct. 31, 2022 Segment
Segment Reporting [Abstract]
Number of business segments	2

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Segment Reporting Information [Line Items]
Net sales	$ 54,564	$ 39,031	$ 104,687	$ 78,524
Intersegment revenues	0	0	0	0
Earnings (loss) before income taxes	456	(2,887)	116	(3,943)
Corporate / Eliminations
Segment Reporting Information [Line Items]
Net sales	0	0	0	0
Intersegment revenues	(3,985)	(741)	(6,402)	(1,481)
Earnings (loss) before income taxes	(1,891)	(1,370)	(3,423)	(2,881)
Domestic Operations | Operating Segments
Segment Reporting Information [Line Items]
Net sales	37,991	29,934	75,459	59,597
Intersegment revenues	650	170	1,446	345
Earnings (loss) before income taxes	491	(2,095)	589	(2,304)
International Operations | Operating Segments
Segment Reporting Information [Line Items]
Net sales	16,573	9,097	29,228	18,927
Intersegment revenues	3,335	571	4,956	1,136
Earnings (loss) before income taxes	$ 1,856	$ 578	$ 2,950	$ 1,242